Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SeVALENT™
Bexson’s formulation platform, branded as SeVALENT™, is the basis for the Company’s lead ketamine therapy, BB106. The Company believes this patent allowance expands the potential utility of its formulation technology, SeVALENT™, to other small molecules. SeVALENT™ is designed to enable intravenous (IV)-only therapies to now be delivered subcutaneously in a controlled manner for use in the home setting.
This Wearable Ketamine Device Could Be The Future Of Pain Management
Currently in the middle of a $4 million Series A funding round, Bexson is still in pre-clinical development. The research stage company will start animal testing this year, with plans to launch a phase one clinical trial in 2021. Peterson says if all goes well, Bexson’s wearable ketamine delivery system could be approved by the FDA for post-op pain by 2026.
Bexson Biomedical To Co-Host Virtual Ketamine Conference
Bexson Biomedical, Inc. will be co-hosting "The Ketamine Conference – A Molecular Masterclass" on August 21-22. The two-day virtual conference will include 12 different panel sessions focused on the latest science, clinical innovations, and investment opportunities with ketamine. Experts from around the globe will be participating as panel speakers and moderators.
Bexson Biomedical Announces New Appointment to Board of Directors
Bexson Biomedical, Inc. today announced the expansion of its Board of Directors with the addition of Itai Danovitch, MD, MBA. Dr. Danovitch is an independent director and brings extensive experience guiding innovative biopharma companies from start-up through accelerated growth.
Bexson Biomedical's Chief Scientific Officer Speaks to Ketamine Leaders at ASKP Conference
Bexson Biomedical's Chief Scientific Officer, Jeffrey Becker, M.D., recently spoke at the annual meeting for the American Society of Ketamine Physicians (ASKP) in Denver, CO. Clinicians and multi-disciplinary thought leaders from around the country and world attended ASKP's two-day conference focused on the latest research and clinical best practices for ketamine, a drug that is finding increasing utility for a wide range of disorders in pain management and mental health.